Skip to main content

Even More Cuts

GlaxoSmithKline is going to announce more than 3,000 job cuts, reports the Financial Times, though the UK’s Times Online put that number closer to 4,000. The Times says the losses will be in Europe and the US and are “part of [the company’s] plans to restructure its workforce and focus increasingly on emerging markets.” The changes will affect administration, manufacturing, sales, and research staff, the Financial Times adds.

If made, this announcement will come on the heels of AstraZeneca's plan to cut 8,000 jobs.

HT: Wall Street Journal Health blog

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.